Elicera Therapeutics has entered into agreements with Carnegie Investment Bank AB (publ) regarding the position as Certified Adviser and Liquidity provider. Carnegie Investment Bank AB (publ) will take over as Certified Adviser and Liquidity provider on November 30, 2023. Until then, Erik Penser Bank AB will continue to act as Certified Adviser and Liquidity provider to the company.
The information was submitted for publication distributed through the contact person below at 08;12 CET on November 30, 2023.
For further information please contact:
Jamal El-Mosleh, CEO, Elicera Therapeutics AB
Phone: +46 (0) 703 31 90 51
The Company’s Certified Adviser is Carnegie Investment Bank AB (publ).
About the iTANK platform
The company’s own fully developed and commercially available iTANK technology platform has been developed for arming and enhancing CAR T-cells to meet two of the major challenges CAR T-cell therapies face in the treatment of solid tumors: tumor antigen heterogeneity and a hostile tumor microenvironment. The technology is used to incorporate a transgene into CAR T-cells encoding a neutrophil activating protein (NAP) from the bacterium Helicobacter pylori. NAP secreted from the CAR(NAP) T-cells has been shown to be able to enhance the function of CAR T-cells and importantly activating a parallel bystander immune response against the cancer via CD8+ killer T-cells. This is expected to lead to a broad attack against most antigen targets on cancer cells. The iTANK platform is used to enhance the company’s own CAR T-cells but can also be universally applied to other CAR T-cell therapies under development. Proof-of-concept data was published in Nature Biomedical Engineering in April 2022. The publication, titled “CAR T cells expressing a bacterial virulence factor trigger potent bystander antitumour responses in solid cancers” (DOI number: 10.1038/s41551-022-00875-5) can be found here: https://www.nature.com/articles/s41551-022-00875-5. More information about iTANK platform is available here: https://www.elicera.com/technology
About Elicera Therapeutics AB
Elicera Therapeutics AB (publ) has developed the patented genetic engineering method iTANK, which makes it possible to develop completely new treatments and refine existing CAR T-cell therapies against aggressive and recurrent cancers. Elicera Therapeutics thus has access to a well-defined and extensive market. The company's CAR T-cell therapies have shown in preclinical studies a potent effect against solid tumors, which are known to be difficult to treat and constitute the majority of cancers. The company addresses an international market worth billions in cell therapy development by offering non-exclusive out-licensing of iTANK to players in the pharmaceutical industry. In parallel, Elicera Therapeutics is running four internal immunotherapy development projects, all of which have the potential to generate significant revenues in the form of exclusive licensing agreements. The company's shares are traded on Nasdaq First North Growth Market. For more information, visit www.elicera.com.